Ernexa Therapeutics Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Ernexa Therapeutics Inc. (ERNA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $5.80 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2021-03-11
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $1.18M, a 77.26% decline year-over-year.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $1.48M, a 67.75% decline year-over-year.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $754.00K, a 85.57% decline year-over-year.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $2.39M, a 50.46% decline year-over-year.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $5.80M, a 70.72% decline from fiscal 2019.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $19.81M, a 15.12% decline from fiscal 2018.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $23.34M, a 9.69% increase from fiscal 2017.
- Ernexa Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2017 was $21.27M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.65M derived: sum of 2 quarters · filed 2021-03-11 | $3.41M derived: sum of 3 quarters · filed 2021-03-11 | $5.80M 10-K · filed 2021-03-11 |
| 2020-09-30 | $1.48M 10-Q · filed 2020-11-13 | $2.23M derived: sum of 2 quarters · filed 2020-11-13 | $4.63M 10-Q · filed 2020-11-13 | $9.79M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | $754.00K 10-Q · filed 2020-08-07 | $3.15M 10-Q · filed 2020-08-07 | $8.32M derived: sum of 3 quarters · filed 2021-03-11 | $12.90M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | $2.39M 10-Q · filed 2020-05-20 | $7.56M derived: sum of 2 quarters · filed 2021-03-11 | $12.14M derived: sum of 3 quarters · filed 2021-03-11 | $17.37M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $9.75M derived: sum of 2 quarters · filed 2021-03-11 | $14.97M derived: sum of 3 quarters · filed 2021-03-11 | $19.81M 10-K · filed 2021-03-11 |
| 2019-09-30 | $4.58M 10-Q · filed 2020-11-13 | $9.81M derived: sum of 2 quarters · filed 2020-11-13 | $14.64M 10-Q · filed 2020-11-13 | $20.56M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $5.23M 10-Q · filed 2020-08-07 | $10.06M 10-Q · filed 2020-08-07 | $15.98M derived: sum of 3 quarters · filed 2020-08-07 | $21.98M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $4.83M 10-Q · filed 2020-05-20 | $10.75M derived: sum of 2 quarters · filed 2020-05-20 | $16.75M derived: sum of 3 quarters · filed 2020-05-20 | $22.41M derived: sum of 4 quarters · filed 2020-05-20 |
| 2018-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $11.92M derived: sum of 2 quarters · filed 2020-03-19 | $17.57M derived: sum of 3 quarters · filed 2020-03-19 | $23.34M 10-K · filed 2020-03-19 |
| 2018-09-30 | $6.00M 10-Q · filed 2019-11-01 | $11.65M derived: sum of 2 quarters · filed 2019-11-01 | $17.42M 10-Q · filed 2019-11-01 | $22.71M derived: sum of 4 quarters · filed 2019-11-01 |
| 2018-06-30 | $5.65M 10-Q · filed 2019-08-12 | $11.41M 10-Q · filed 2019-08-12 | $16.71M derived: sum of 3 quarters · filed 2019-08-12 | $21.91M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $5.76M 10-Q · filed 2019-05-14 | $11.06M derived: sum of 2 quarters · filed 2019-05-14 | $16.25M derived: sum of 3 quarters · filed 2019-05-14 | $21.80M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $10.49M derived: sum of 2 quarters · filed 2019-03-22 | $16.04M derived: sum of 3 quarters · filed 2019-03-22 | $21.27M 10-K · filed 2019-03-22 |
| 2017-09-30 | $5.20M 10-Q · filed 2018-11-09 | $10.75M derived: sum of 2 quarters · filed 2018-11-09 | $15.98M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $5.55M 10-Q · filed 2018-08-06 | $10.78M 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |